• Dilon Technologies (Newport News, Virginia) reported the introduction of the Dilon 6800 Access, a transportable version of the Dilon 6800 gamma camera designed to meet the needs of customers that want to move the camera between medical centers. The transportable camera will expand the clinical use of the Dilon 6800, by providing the flexibility of transporting the camera to areas of need that may not have high enough patient volumes to justify a full-time system — such as small community hospitals. Shared Medical Technology (SMT; Rice Lake, Wisconsin) is the first center to use the Dilon 6800 Access. SMT has been providing community hospitals and clinics with diagnostic services for over 30 years.

• Exact Sciences (Marlborough, Massachusetts) reported publication of a study in which stool and blood plasma were assessed in a head-to-head comparison for the detection of colorectal cancer (CRC). Using an improved BEAMing DNA detection technology from Johns Hopkins University (Baltimore), study data demonstrated a 92% sensitivity for detecting CRC in stool samples — BEAMing incorporating the use of "beads, emulsion, amplification, and magnetism." BEAMing stool-based DNA testing outperformed blood plasma testing, especially for the detection of early stage CRC. The technology is a method for performing single-molecule analysis of DNA, or "digital PCR," demonstrated to provide a high level of sensitivity for detecting mutations or deletions in gene sequences of interest. Exact uses applied genomics to make screening technologies for use in the detection of cancer.

• GE Healthcare (Waukesha, Wisconsin) reported release of a new pre-clinical computed tomography (CT) scanner designed to accelerate research for cardiovascular disease and drug development. The GE eXplore CT 120 scanner uses X-ray-source technology derived from clinical systems, the company saying that it features 100 times the output of previous GE laboratory research imaging systems and enables X-ray exposures fast enough and detailed enough to capture the motion of a beating mouse heart. This thus brings cardiac CT imaging to an animal often used in disease research and drug development. The scanner features industry-standard DICOM compatibility and an optional analysis workstation to assist in image analysis and production of research data, according to the company.

• HemCon Medical Technologies (Portland, Oregon) reported new antibacterial indications approved by the FDA, including a barrier against methicillin-resistant Staphylococcus aureus (MRSA), for its HemCon bandages, ChitoFlex dressings and KytoStat bandages. The hemostatic HemCon Bandage and ChitoFlex dressing are now approved with an antibacterial barrier indication against a wide range of harmful organisms, including MRSA, Enterococcus faecalis and Acinetobacter baumannii. HemCon's bandages, created from a natural substance in shrimp shells called chitosan, stop bleeding – including extensive arterial bleeding – within two to five minutes. The antibacterial barrier properties of the bandages help prevent infection transmission to other patients and healthcare providers and also make it easier for medical professionals to help prevent infections at incision-site wounds.

• ICON (Dublin, Ireland) said that its medical imaging division has become the first commercial imaging core laboratory to offer quantitative coronary angiographic (QCA) analysis with an integrated electronic case report form. This new service has been made possible through the integration of QCAPlus, a QCA application from Sanders Data Systems, with an eCRF within ICON Medical Imaging's proprietary Medical Image Review and Analysis (MIRA) system. The integration of QCAPlus adds to the existing visualization, analysis and project management applications currently available through MIRA. The company provides outsourced services to the pharmaceutical, biotechnology and medical device industries.

• Inverness Medical Innovations (Waltham, Massachusetts) said that it has received licensure from the U.S. Department of Agriculture (USDA) to make the BinaxNOW Avian Influenza Virus Type A Antigen Test Kit. The BinaxNOW AI Antigen Test is an immunochromatographic test (ICT) that detects influenza A nucleoproteins in chicken, turkey and duck samples. No specialized equipment or training is necessary. Use of the BinaxNOW AI test enables early and accurate identification of influenza A nucleoproteins, facilitating the implementation of appropriate and cost-effective action plans. Inverness Medical Innovations makes near-patient diagnostics, monitoring and health management solutions.

• Nova (Waltham, Massachusetts) is offering a software enhancement for its StatStrip Glucose and StatSensor Creatinine point-of-care monitoring systems that allow off-line entry of POC test results for immediate data capture. With the enhanced NovaNet instrument manager software, operators can use StatStrip touch screen to manually enter almost any off-line POC test result, such as pregnancy or urinalysis, and use the meter as a POC communication device to transmit the information to the hospital's electronic database. The NovaNet open system architecture allows results and reporting to be entirely user configurable. StatStrip and StatSensor meters can be pre-configured so that test results can be entered numerically, via multiple choice, or text. Results are displayed along with normal and abnormal ranges. QC results can be entered as well. Nova StatStrip Glucose and StatSensor Creatinine are handheld, whole blood meters for point-of-care testing.

No Comments